

Contains
 Exact Match
 Begins With
 Name
 Code
 Property
 Relationship

[Back to search results](#)
[Advanced Search](#)

Version: 18.03d (Release date: 2018-03-26)

[Hierarchy](#) | [Value Sets](#) | [Maps](#)
[Help](#)

[View in Hierarchy](#) | [View History](#) | [View Graph](#) | [Add to Cart](#) | [Suggest Changes](#)

Daratumumab (Code C74007)

[Terms & Properties](#) | [Synonym Details](#) | [Relationships](#) | [Mappings](#) | [View All](#)

Table of Contents

- [Terms & Properties](#)
- [Synonym Details](#)
- [Relationships](#)
- [Mapping Details](#)

Terms & Properties

Preferred Name: Daratumumab

Definition: A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of anti-CD38 monoclonal antibody to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells.

Display Name: Daratumumab

Label: Daratumumab

NCI Thesaurus Code: C74007 ([Search for linked caDSR metadata](#)) ([search value sets](#))

NCI Metathesaurus Link: C2346801 ([see NCI Metathesaurus info](#))

Synonyms & Abbreviations: ([see Synonym Details](#))

Anti-CD38 Monoclonal Antibody
 Daratumumab
 DARATUMUMAB
 Darzalex
 HuMax-CD38
 JNJ-54767414

External Source Codes:

CAS Registry Number	945721-28-8 (see NLM ChemIDplus info)
FDA UNII Code	4Z63YK6E0E
PDQ Closed Trial Search ID	583564
PDQ Open Trial Search ID	583564 (check for NCI PDQ open clinical trial info)
UMLS CUI	C2346801

Other Properties:

Name	Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For_code	multiple myeloma C74007
Contributing_Source	CTRP
Contributing_Source	FDA
Legacy_Concept_Name	Anti-CD38_Monoclonal_Antibody
Semantic_Type	Pharmacologic Substance

Additional Concept Data:

Defined Fully by Roles: No

 URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&version=18.03d&ns=ncit&code=C74007

Synonym Details

Term	Source <input data-bbox="523 1809 544 1839" type="button" value="?"/>	Type <input data-bbox="842 1809 863 1839" type="button" value="?"/>	Code
Anti-CD38 Monoclonal Antibody	NCI	SY	
DARATUMUMAB	FDA	PT	4Z63YK6E0E
Daratumumab	NCI	PT	
Darzalex	NCI	BR	
HuMax-CD38	NCI	SY	
JNJ-54767414	NCI	CN	

Relationships with other NCI Thesaurus Concepts

Parent Concepts:

[Antineoplastic Antibody](#)
[Monoclonal Antibody](#)

Child Concepts: (none)

Role Relationships, asserted or inherited, pointing from the current concept to other concepts:
(*True for the current concept and its descendants, may be inherited from parent(s).*)

Relationship	Value (qualifiers indented underneath)
Biological Process	
Chemical_Or_Drug_Has_Mechanism_Of_Action	Antigen Binding

Associations pointing from the current concept to other concepts:
(*True for the current concept.*)

Relationship	Value (qualifiers indented underneath)
Concept_In_Subset	CTRP Agent Terminology
Concept_In_Subset	CTRP Terminology
Concept_In_Subset	FDA Established Names and Unique Ingredient Identifier Codes Terminology
Concept_In_Subset	NCIt Antineoplastic Agent Terminology

Incoming Role Relationships, asserted or inherited, pointing from other concepts to the current concept:

Value (qualifiers indented underneath)	Relationship
Chemotherapy Regimen or Agent Combination	
Daratumumab/Bortezomib/Dexamethasone Regimen	Chemotherapy_Regimen_Has_Component
Daratumumab/Lenalidomide/Dexamethasone Regimen	Chemotherapy_Regimen_Has_Component

Incoming Associations pointing from other concepts to the current concept: (*none*)

Mapping relationships:

[see Mappings](#)

[Mapping Details](#)

Mapping through NCI Metathesaurus:

[C2346801](#)

Maps To:

Maps From:

Mapping Source: PDQ_2016_07_31_TO_NCI_2016_10E

Source	Source Code	Source Name	REL	Target	Target Code	Target Name
PDQ	CDR0000583564	daratumumab	SY	NCI	C74007	Daratumumab

[NCI Home](#) | [Contact Us](#) | [Policies](#) | [Accessibility](#) | [FOIA](#)

[U.S. Department of Health and Human Services](#) | [National Institutes of Health](#) | [National Cancer Institute](#) | [USA.gov](#)